{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:43:03Z","timestamp":1792712583945,"version":"4.5.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008487","name":"Cure Parkinson\u2019s Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008487","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003136","name":"Edmond J. Safra Philanthropic Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003136","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000263","name":"Parkinson Society Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000263","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1016\/j.neuropharm.2012.06.012","type":"journal-article","created":{"date-parts":[[2012,6,18]],"date-time":"2012-06-18T18:56:36Z","timestamp":1340045796000},"page":"829-836","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["l-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease"],"prefix":"10.1016","volume":"63","author":[{"given":"Philippe","family":"Huot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom H.","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James B.","family":"Koprich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan H.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan M.","family":"Brotchie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2012.06.012_bib1","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1212\/WNL.44.8.1491","article-title":"Effect of plasma levels of large neutral amino acids and degree of parkinsonism on the blood-to-brain transport of levodopa in naive and MPTP parkinsonian monkeys","volume":"44","author":"Alexander","year":"1994","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2012.06.012_bib2","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ejphar.2003.11.065","article-title":"Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque","volume":"485","author":"Bezard","year":"2004","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2012.06.012_bib3","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1017\/S031716710003849X","article-title":"Risk factors for peak dose dyskinesia in 100 levodopa-treated parkinsonian patients","volume":"23","author":"Blanchet","year":"1996","journal-title":"Can. J. Neurol. Sci."},{"key":"10.1016\/j.neuropharm.2012.06.012_bib4","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1002\/mds.870130507","article-title":"Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys","volume":"13","author":"Blanchet","year":"1998","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2012.06.012_bib5","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1124\/jpet.107.125666","article-title":"Blockade of cannabinoid type 1 receptors augments the antiparkinsonian action of levodopa without affecting dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated rhesus monkeys","volume":"323","author":"Cao","year":"2007","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2012.06.012_bib6","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1097\/00002826-199012000-00006","article-title":"Effect of nitecapone (OR-462) on the pharmacokinetics of levodopa and 3-O-methyldopa formation in cynomolgus monkeys","volume":"13","author":"Cedarbaum","year":"1990","journal-title":"Clin. Neuropharmacol."},{"issue":"Suppl. 1","key":"10.1016\/j.neuropharm.2012.06.012_bib7","first-page":"278","article-title":"Correlation of plasma with CSF DOPA and dopamine concentrations in the rat after l-DOPA administration [Abstract]","volume":"108","author":"Chang","year":"1993","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2012.06.012_bib8","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1212\/WNL.44.7.1287","article-title":"Longitudinal monitoring of the levodopa concentration-effect relationship in Parkinson's disease","volume":"44","author":"Contin","year":"1994","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2012.06.012_bib9","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/00002826-199508000-00005","article-title":"Acute effects of COMT inhibition on l-DOPA pharmacokinetics in patients treated with carbidopa and selegiline","volume":"18","author":"Davis","year":"1995","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.neuropharm.2012.06.012_bib10","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1093\/clinchem\/43.5.740","article-title":"Microdialysis-HPLC for plasma levodopa and metabolites monitoring in parkinsonian patients","volume":"43","author":"Dethy","year":"1997","journal-title":"Clin. Chem."},{"key":"10.1016\/j.neuropharm.2012.06.012_bib11","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/0006-8993(86)90782-1","article-title":"Long-term effects of MPTP on central and peripheral catecholamine and indoleamine concentrations in monkeys","volume":"379","author":"Di Paolo","year":"1986","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2012.06.012_bib12","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1600-0404.1999.tb00386.x","article-title":"L-dopa pharmacokinetics studied with microdialysis in patients with Parkinson's disease and a history of malignant melanoma","volume":"100","author":"Dizdar","year":"1999","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.neuropharm.2012.06.012_bib13","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1007\/BF01485901","article-title":"Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system","volume":"38","author":"Ehringer","year":"1960","journal-title":"Klin. Wochenschr."},{"key":"10.1016\/j.neuropharm.2012.06.012_bib14","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/0006-8993(87)90211-3","article-title":"Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on catecholamines and metabolites in primate brain and CSF","volume":"415","author":"Elsworth","year":"1987","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2012.06.012_bib15","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1002\/mds.21475","article-title":"Levodopa-induced dyskinesias","volume":"22","author":"Fabbrini","year":"2007","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2012.06.012_bib16","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/ana.410210409","article-title":"Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease","volume":"21","author":"Fabbrini","year":"1987","journal-title":"Ann. Neurol."},{"issue":"Suppl. 3","key":"10.1016\/j.neuropharm.2012.06.012_bib17","doi-asserted-by":"crossref","first-page":"S497","DOI":"10.1002\/mds.22028","article-title":"The history of dopamine and levodopa in the treatment of Parkinson's disease","volume":"23","author":"Fahn","year":"2008","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2012.06.012_bib18","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1212\/WNL.37.6.940","article-title":"Peripheral pharmacokinetics of levodopa in untreated, stable, and fluctuating parkinsonian patients","volume":"37","author":"Gancher","year":"1987","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2012.06.012_bib19","doi-asserted-by":"crossref","first-page":"14338","DOI":"10.1523\/JNEUROSCI.4223-07.2007","article-title":"RGS9-2 negatively modulates L-3,4-dihydroxyphenylalanine-induced dyskinesia in experimental Parkinson's disease","volume":"27","author":"Gold","year":"2007","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2012.06.012_bib20","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1136\/jnnp.16.4.213","article-title":"The brain-stem lesions in Parkinsonism","volume":"16","author":"Greenfield","year":"1953","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.neuropharm.2012.06.012_bib21","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/ana.410270507","article-title":"l-dopa pharmacokinetics in plasma and cisternal and lumbar cerebrospinal fluid of monkeys","volume":"27","author":"Hammerstad","year":"1990","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2012.06.012_bib22","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1365-2125.1986.tb02913.x","article-title":"The pharmacokinetics of intravenous and oral levodopa in patients with Parkinson's disease who exhibit on-off fluctuations","volume":"22","author":"Hardie","year":"1986","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2012.06.012_bib23","doi-asserted-by":"crossref","DOI":"10.1002\/mds.23861","article-title":"Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease","author":"Hauser","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2012.06.012_bib24","first-page":"19","article-title":"Biochemical pathophysiology of Parkinson's disease","volume":"45","author":"Hornykiewicz","year":"1987","journal-title":"Adv. Neurol."},{"key":"10.1016\/j.neuropharm.2012.06.012_bib25","doi-asserted-by":"crossref","first-page":"7190","DOI":"10.1523\/JNEUROSCI.1171-11.2011","article-title":"Characterization of 3,4-methylenedioxymethamphetamine (MDMA) enantiomers in\u00a0vitro and in the MPTP-Lesioned primate: R-MDMA reduces severity of dyskinesia, whereas S-MDMA extends duration of ON-time","volume":"31","author":"Huot","year":"2011","journal-title":"J.\u00a0Neurosci."},{"issue":"194","key":"10.1016\/j.neuropharm.2012.06.012_bib26","article-title":"5-HT2A receptor levels increase in MPTP-lesioned macaques treated chronically with l-DOPA","volume":"33","author":"Huot","year":"2012","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuropharm.2012.06.012_bib27","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jchemneu.2007.06.004","article-title":"l-Dopa treatment abolishes the numerical increase in striatal dopaminergic neurons in parkinsonian monkeys","volume":"35","author":"Huot","year":"2008","journal-title":"J.\u00a0Chem. Neuroanat."},{"key":"10.1016\/j.neuropharm.2012.06.012_bib28","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0165-0270(99)00184-3","article-title":"Comparison of eight clinical rating scales used for the assessment of MPTP-induced parkinsonism in the Macaque monkey","volume":"96","author":"Imbert","year":"2000","journal-title":"J.\u00a0Neurosci. Methods"},{"key":"10.1016\/j.neuropharm.2012.06.012_bib29","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nrn2471","article-title":"Molecular mechanisms of l-DOPA-induced dyskinesia","volume":"9","author":"Jenner","year":"2008","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2012.06.012_bib30","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0304-3940(84)90467-1","article-title":"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset","volume":"50","author":"Jenner","year":"1984","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2012.06.012_bib31","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1124\/jpet.110.166629","article-title":"Reduction of l-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease","volume":"333","author":"Johnston","year":"2010","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2012.06.012_bib32","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1002\/mds.23172","article-title":"The alpha adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primates","volume":"25","author":"Johnston","year":"2010","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2012.06.012_bib33","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1002\/mds.23069","article-title":"Effect of histamine H2 receptor antagonism on levodopa-induced dyskinesia in the MPTP-macaque model of Parkinson's disease","volume":"25","author":"Johnston","year":"2010","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2012.06.012_bib34","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/j.1476-5381.1990.tb14085.x","article-title":"The effect of benserazide on the peripheral and central distribution and metabolism of levodopa after acute and chronic administration in the rat","volume":"100","author":"Kent","year":"1990","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2012.06.012_bib35","doi-asserted-by":"crossref","first-page":"234","DOI":"10.2174\/157488407781668802","article-title":"The pharmacokinetics and pharmacodynamics of levodopa in the treatment of Parkinson's disease","volume":"2","author":"Khor","year":"2007","journal-title":"Curr. Clin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2012.06.012_bib36","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1002\/mds.23631","article-title":"The selective mu-opioid receptor antagonist adl5510 reduces levodopa-induced dyskinesia without affecting antiparkinsonian action in mptp-lesioned macaque model of Parkinson's disease","volume":"26","author":"Koprich","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2012.06.012_bib37","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/bdd.558","article-title":"Investigation of the impact of sarizotan on the pharmacokinetics of levodopa","volume":"28","author":"Krosser","year":"2007","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.neuropharm.2012.06.012_bib38","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1056\/NEJM199810153391607","article-title":"Parkinson's disease. Second of two parts","volume":"339","author":"Lang","year":"1998","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2012.06.012_bib39","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1126\/science.6823561","article-title":"Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis","volume":"219","author":"Langston","year":"1983","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2012.06.012_bib40","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJM198308043090511","article-title":"Parkinson's disease in a chemist working with 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine","volume":"309","author":"Langston","year":"1983","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2012.06.012_bib41","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/0006-8993(84)90777-7","article-title":"Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey","volume":"292","author":"Langston","year":"1984","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2012.06.012_bib42","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0022-3565(25)30363-0","article-title":"The neurochemistry of Parkinson's disease: effect of l-dopa therapy","volume":"195","author":"Lloyd","year":"1975","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2012.06.012_bib43","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0165-0270(00)00283-1","article-title":"Comparison by microdialysis of striatal l-DOPA after its systemic administration in rats with probes implanted acutely or through a guide cannula","volume":"102","author":"Marburger","year":"2000","journal-title":"J.\u00a0Neurosci. Methods"},{"key":"10.1016\/j.neuropharm.2012.06.012_bib44","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1212\/WNL.32.5.514","article-title":"The mysterious motor function of the basal ganglia: the Robert Wartenberg Lecture","volume":"32","author":"Marsden","year":"1982","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2012.06.012_bib45","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.neuropharm.2009.12.024","article-title":"Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys","volume":"58","author":"Morin","year":"2010","journal-title":"Neuropharmacology"},{"issue":"Suppl. 3","key":"10.1016\/j.neuropharm.2012.06.012_bib46","first-page":"III\/47","article-title":"Pharmacokinetics of l-dopa. Special reference to food and aging","volume":"253","author":"Murata","year":"2006","journal-title":"J.\u00a0Neurol."},{"key":"10.1016\/j.neuropharm.2012.06.012_bib47","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.parkreldis.2010.08.019","article-title":"Fluctuation in plasma entacapone concentrations in accordance with variable plasma levodopa concentrations","volume":"16","author":"Nagai","year":"2010","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.neuropharm.2012.06.012_bib48","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/00002826-199901000-00005","article-title":"Pharmacokinetics and pharmacodynamics of l-Dopa after acute and 6-week tolcapone administration in patients with Parkinson's disease","volume":"22","author":"Napolitano","year":"1999","journal-title":"Clin. Neuropharmacol."},{"issue":"Suppl. 1","key":"10.1016\/j.neuropharm.2012.06.012_bib49","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/S1353-8020(09)70007-0","article-title":"Inter- and intra-individual variation in l-dopa pharmacokinetics in the treatment of Parkinson's disease","volume":"15","author":"Nomoto","year":"2009","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.neuropharm.2012.06.012_bib50","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1212\/WNL.36.6.739","article-title":"Levodopa pharmacokinetics and pharmacodynamics in fluctuating parkinsonian patients","volume":"36","author":"Nutt","year":"1986","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2012.06.012_bib51","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/ana.410180505","article-title":"The effect of carbidopa on the pharmacokinetics of intravenously administered levodopa: the mechanism of action in the treatment of parkinsonism","volume":"18","author":"Nutt","year":"1985","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2012.06.012_bib52","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1212\/WNL.44.5.913","article-title":"Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients","volume":"44","author":"Nutt","year":"1994","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2012.06.012_bib53","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1212\/WNL.36.9.1206","article-title":"Clinical and biochemical studies with controlled-release levodopa\/carbidopa","volume":"36","author":"Nutt","year":"1986","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2012.06.012_bib54","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0022-510X(84)90003-0","article-title":"Dopamine metabolism in the central nervous system after discontinuation of l-dopa therapy in patients with Parkinson disease","volume":"66","author":"Ogasahara","year":"1984","journal-title":"J.\u00a0Neurol. Sci."},{"key":"10.1016\/j.neuropharm.2012.06.012_bib55","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/ana.410290516","article-title":"Temporal relationships between plasma and cerebrospinal fluid pharmacokinetics of levodopa and clinical effect in Parkinson's disease","volume":"29","author":"Olanow","year":"1991","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2012.06.012_bib56","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1007\/s002130100733","article-title":"l-dopa induces dyskinesia in\u00a0normal monkeys: behavioural and pharmacokinetic observations","volume":"156","author":"Pearce","year":"2001","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2012.06.012_bib57","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/ana.21203","article-title":"Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys","volume":"62","author":"Quik","year":"2007","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2012.06.012_bib58","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1212\/WNL.25.12.1144","article-title":"On-off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients","volume":"25","author":"Shoulson","year":"1975","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2012.06.012_bib59","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/0304-3940(95)11636-B","article-title":"Effects of the catechol-O-methyltransferase inhibitor tolcapone in Parkinson's disease: correlations between concentrations of dopaminergic substances in the plasma and cerebrospinal fluid and clinical improvement","volume":"192","author":"Tohgi","year":"1995","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2012.06.012_bib60","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1124\/jpet.108.144097","article-title":"Alpha1-adrenoceptors mediate dihydroxyphenylalanine-induced activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaques","volume":"328","author":"Visanji","year":"2009","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2012.06.012_bib61","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1212\/WNL.43.9.1704","article-title":"The effect of l-dopa infusions with and without phenylalanine challenges in parkinsonian patients: plasma and ventricular CSF l-dopa levels and clinical responses","volume":"43","author":"Woodward","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2012.06.012_bib62","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.brainres.2003.08.065","article-title":"Pharmacokinetics of l-dopa in plasma and extracellular fluid of striatum in common marmosets","volume":"993","author":"Zhang","year":"2003","journal-title":"Brain Res."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390812002705?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390812002705?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T23:54:02Z","timestamp":1762214042000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390812002705"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":62,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["S0028390812002705"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2012.06.012","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"l-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2012.06.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}